Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages : The PSERENADE project
| dc.contributor.author | The PSERENADE Team | |
| dc.contributor.department | Faculty of Medicine | |
| dc.date.accessioned | 2025-11-20T09:50:32Z | |
| dc.date.available | 2025-11-20T09:50:32Z | |
| dc.date.issued | 2025-03 | |
| dc.description | Publisher Copyright: © 2025 The Author(s) | en |
| dc.description.abstract | Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited. | en |
| dc.description.version | Peer reviewed | en |
| dc.format.extent | 4130547 | |
| dc.format.extent | ||
| dc.identifier.citation | The PSERENADE Team 2025, 'Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages : The PSERENADE project', Journal of Infection, vol. 90, no. 3, 106426. https://doi.org/10.1016/j.jinf.2025.106426 | en |
| dc.identifier.doi | 10.1016/j.jinf.2025.106426 | |
| dc.identifier.issn | 0163-4453 | |
| dc.identifier.other | 236540201 | |
| dc.identifier.other | a22e63bd-f1b2-454f-96de-23ad42b867f5 | |
| dc.identifier.other | 85217119857 | |
| dc.identifier.other | 39864526 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.11815/7794 | |
| dc.language.iso | en | |
| dc.relation.ispartofseries | Journal of Infection; 90(3) | en |
| dc.relation.url | https://www.scopus.com/pages/publications/85217119857 | en |
| dc.rights | info:eu-repo/semantics/openAccess | en |
| dc.subject | Incidence | en |
| dc.subject | Indirect protection | en |
| dc.subject | Pneumococcal conjugate vaccines | en |
| dc.subject | Pneumococcal meningitis | en |
| dc.subject | Serotype replacement | en |
| dc.subject | Serotypes | en |
| dc.subject | Vaccine impact | en |
| dc.subject | sýklafræði | en |
| dc.subject | Microbiology (medical) | en |
| dc.subject | Infectious Diseases | en |
| dc.title | Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages : The PSERENADE project | en |
| dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | en |
Skrár
Original bundle
1 - 1 af 1
- Nafn:
- 1-s2.0-S0163445325000209-main.pdf
- Stærð:
- 3.94 MB
- Snið:
- Adobe Portable Document Format